Nephrocalcinosis
Return to Library
|
Free Nephrocalcinosis Articles |
|
|
|
|
Investigators at University of Nebraska target nephrocalcinosis
2009 MAY 11 - (NewsRx.com) -- According to recent research published in the Journal of Endourology, "Sodium thiosulfate (STS) is a U. S. Food and Drug Administration (FDA) -approved chelating agent that is used for the treatment of cyanide poisoning and prophylaxis against cisplatin nephropathy. Recently, STS has also been used in the treatment of calciphylaxis, which is a disease characterized by calcification in the soft tissues with vascular calcification and thrombosis causing nonhealing ulcers." "We proposed a rat model to evaluate whether STS has any possible beneficial effect on calcium nephrolithiasis or nephrocalcinosis. Twenty-one male Sprague-Dawley rats were used in the study. All animals received standard rat chow throughout the experiment. The animals were started on special drinking water containing 0.4% ethylene glycol plus 1.0% ammonium chloride for 7 days to induce crystalluria and nephrocalcinosis. The animals were then randomized to two groups. Group 1 served as a control and received daily intraperitoneal injections of normal saline. Group 2 received daily intraperitoneal injections of STS solution. Special drinking water containing 0.8% ethylene glycol was continued during the treatment period. Group 2 gained significantly less weight than group 1 (18.0% v 8.5%, p< 0.05). The amount of crystalluria in group 2 was much less than that in group 1, but did not reach statistical significance (0.7 v 4.2, p 0.09). Degree of calcification noted in the kidneys was not statistically different between the two groups. The current study did not reveal any significant benefit of STS administration on calcium stone disease," wrote C.A. Lagrange and colleagues, University of Nebraska. The researchers concluded: "However, many more studies are necessary before the possibility of a beneficial effect is completely disproved." Lagrange and colleagues published their study in the Journal of Endourology (The Effect of Sodium Thiosulfate Administration on Nephrocalcinosis in a Rat Model. Journal of Endourology, 2009;23(3):529-533). For additional information, contact C.A. Lagrange, University of Nebraska, Medical Center, Dept. of Pathology, 982360 Nebraska Med Center, Omaha, NE 68198, USA. The publisher's contact information for the Journal of Endourology is: Mary Ann Liebert Inc., 140 Huguenot Street, 3RD FL, New Rochelle, NY 10801, USA. Keywords: United States, Omaha, Ammonium Chloride, Calciphylaxis, Cisplatin, Dermatology, Drugs, Endourology, FDA, Kidney Calculi, Nephrocalcinosis, Nephrolithiasis, Nephrology, Nephropathy, Pharmaceuticals, Poisoning, Regulatory Actions, Sodium Thiosulfate, Therapy, Thrombosis, Treatment, U.S. Food and Drug Administration, Urology, University of Nebraska. This article was prepared by Biotech Business Week editors from staff and other reports. Copyright 2009, Biotech Business Week via NewsRx.com.
|
